72 related articles for article (PubMed ID: 35461759)
1. Development of an induced pluripotent stem cell-specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products.
Chung L; Cogburn LA; Sui L; Dashnau JL
Cytotherapy; 2022 Jul; 24(7):733-741. PubMed ID: 35461759
[TBL] [Abstract][Full Text] [Related]
2. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
[TBL] [Abstract][Full Text] [Related]
3. Seamless and non-destructive monitoring of extracellular microRNAs during cardiac differentiation from human pluripotent stem cells.
Sekine O; Kanaami S; Masumoto K; Aihara Y; Morita-Umei Y; Tani H; Soma Y; Umei TC; Haga K; Moriwaki T; Kawai Y; Ohno M; Kishino Y; Kanazawa H; Fukuda K; Ieda M; Tohyama S
Stem Cell Reports; 2023 Oct; 18(10):1925-1939. PubMed ID: 37738969
[TBL] [Abstract][Full Text] [Related]
4. Integration of Transcriptome and MicroRNA Profile Analysis of iMSCs Defines Their Rejuvenated State and Conveys Them into a Novel Resource for Cell Therapy in Osteoarthritis.
Konteles V; Papathanasiou I; Tzetis M; Goussetis E; Trachana V; Mourmoura E; Balis C; Malizos K; Tsezou A
Cells; 2023 Jun; 12(13):. PubMed ID: 37443790
[TBL] [Abstract][Full Text] [Related]
5. The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
Mehra V; Chhetri JB; Ali S; Roddie C
Biology (Basel); 2023 Nov; 12(11):. PubMed ID: 37998018
[TBL] [Abstract][Full Text] [Related]
6. iPSC-Derived Natural Killer Cells for Cancer Immunotherapy.
Karagiannis P; Kim SI
Mol Cells; 2021 Aug; 44(8):541-548. PubMed ID: 34373366
[TBL] [Abstract][Full Text] [Related]
7. Platforms for Manufacturing Allogeneic, Autologous and iPSC Cell Therapy Products: An Industry Perspective.
Abraham E; Ahmadian BB; Holderness K; Levinson Y; McAfee E
Adv Biochem Eng Biotechnol; 2018; 165():323-350. PubMed ID: 28534167
[TBL] [Abstract][Full Text] [Related]
8. Profiling of naïve and primed human pluripotent stem cells reveals state-associated miRNAs.
Dodsworth BT; Hatje K; Rostovskaya M; Flynn R; Meyer CA; Cowley SA
Sci Rep; 2020 Jun; 10(1):10542. PubMed ID: 32601281
[TBL] [Abstract][Full Text] [Related]
9. Development of Immune Cell Therapy Using T Cells Generated from Pluripotent Stem Cells.
Kawamoto H; Masuda K; Nagano S
Adv Exp Med Biol; 2024; 1444():207-217. PubMed ID: 38467982
[TBL] [Abstract][Full Text] [Related]
10. iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation.
Zhang Y; Shi Q; Wang P; Huang C; Tang S; Zhou M; Hu Q; Wu L; Liang D
MedComm (2020); 2024 May; 5(5):e553. PubMed ID: 38737469
[TBL] [Abstract][Full Text] [Related]
11. Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation.
Netsrithong R; Garcia-Perez L; Themeli M
Front Immunol; 2023; 14():1325209. PubMed ID: 38283344
[TBL] [Abstract][Full Text] [Related]
12. Selection of iPSCs without mtDNA deletion for autologous cell therapy in a patient with Pearson syndrome.
Lee Y; Han J; Hwang SB; Kang SS; Son HB; Jin C; Kim JE; Lee BH; Kang E
BMB Rep; 2023 Aug; 56(8):463-468. PubMed ID: 37156631
[TBL] [Abstract][Full Text] [Related]
13. Analysis of three characterization assays reveals ddPCR of LIN28A as the most sensitive for the detection of residual pluripotent stem cells in cellular therapy products.
Sun J; Yates C; Dingwall S; Ongtengco C; Power D; Gray P; Prowse A
Cytotherapy; 2024 May; ():. PubMed ID: 38934983
[TBL] [Abstract][Full Text] [Related]
14. Estimating residual undifferentiated cells in human chemically induced pluripotent stem cell derived islets using lncRNA as biomarkers.
Wu Y; Zhang Z; Wu S; Chen Z; Pu Y
Sci Rep; 2023 Sep; 13(1):16435. PubMed ID: 37777562
[TBL] [Abstract][Full Text] [Related]
15. An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells.
Hsu LJ; Liu CL; Kuo ML; Shen CN; Shen CR
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680440
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Genetic Stability in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Using Droplet Digital PCR.
Park JW; Bae SJ; Yun JH; Kim S; Park M
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256178
[TBL] [Abstract][Full Text] [Related]
17. Novel glycylated sugar alcohols protect ESC-specific microRNAs from degradation in iPS cells.
Chang-Lin S; Hung A; Chang DC; Lin YW; Ying SY; Lin SL
Nucleic Acids Res; 2016 Jun; 44(10):4894-906. PubMed ID: 27001514
[TBL] [Abstract][Full Text] [Related]
18. Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product.
Jha BS; Farnoodian M; Bharti K
Stem Cells Transl Med; 2021 Feb; 10(2):198-208. PubMed ID: 32946199
[TBL] [Abstract][Full Text] [Related]
19. Human iPS Cells for Clinical Applications and Cellular Products.
Lawrence M
Handb Exp Pharmacol; 2023; 281():3-27. PubMed ID: 36964256
[TBL] [Abstract][Full Text] [Related]
20. Immune cells and RBCs derived from human induced pluripotent stem cells: method, progress, prospective challenges.
Jiang JH; Ren RT; Cheng YJ; Li XX; Zhang GR
Front Cell Dev Biol; 2023; 11():1327466. PubMed ID: 38250324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
